"","V1","V2","V3","V4","V5","V6","V7","V8","V9","V10","V11","V12","V13","V14","V15","V16","V17","V18","V19","V20","V21","V22","V23","V24","V25","V26","V27","V28","V29","V30","V31","V32","V33","V34","V35","V36","V37","V38","V39","V40","V41","V42","V43","V44","V45","V46","V47","V48","V49","V50","V51","V52","V53","V54","V55","V56","V57","V58","V59","V60","V61","V62","V63","V64","V65","V66","V67","V68","V69","V70","V71","V72","V73","V74","V75","V76","V77","V78","V79","V80","V81","V82","V83","V84","V85","V86","V87","V88","V89","V90","V91","V92","V93","V94","V95","V96","V97","V98","V99","V100","V101","V102","V103","V104","V105","V106","V107","V108","V109","V110","V111","V112","V113","V114","V115","V116","V117","V118","V119","V120","V121","V122","V123","V124","V125","V126","V127","V128","V129","V130","V131","V132","V133","V134","V135","V136","V137","V138","V139","V140","V141","V142","V143","V144","V145","V146","V147","V148","V149","V150","V151","V152","V153","V154","V155","V156","V157","V158","V159","V160","V161","V162","V163","V164","V165","V166","V167"
"1","abs209.txt","mek","inhibition","is","of","interest","in","cancer","drug","development","","but","clinical","activityin","metastatic","colorectal","(mcrc)","has","been","limited","preclinical","studiesdemonstrated","wnt","pathway","overexpression","kras-mutant","cell","lines","resistant","tothe","inhibitor","selumetinib","the","combination","and","cyclosporin","a","noncanonical","modulator","demonstrated","antitumor","activity","mcrcpatient-derived","xenografts","to","translate","these","results","we","conducted","nci","cancertherapy","evaluation","program-approved","multicenter","phase","i/ib","trial","(nct02188264)","ofthe","patients","with","advanced","solidmalignancies","were","treated","oral","andcyclosporin","dose","escalation","followed","by","an","expansion","cohort","ofirinotecan","oxaliplatin-refractory","mcrc","utilized","asingle-agent","run-in","evaluate","fzd2","biomarker","upregulation","andkras-wt","kras-mt","stratification","identify","any","potential","predictors","ofefficacy","twenty","19","enrolled","expansionphases","respectively","most","common","adverse","events","grade","3/4","toxicitieswere","rash","hypertension","edema","three","dose-limiting","toxicities","(grade","3hypertension","increased","creatinine)","reported","mtd","wasselumetinib","75","mg","twice","daily","2","mg/kg","on","28-daycycle","kras","did","not","differences","response","betweenkras-wt","cancers","two","partial","responses","18","stable","disease","10progressive","observed","well","tolerated","evidence","futurestrategies","for","concept","include","identifying","better","improved","modulation","significance","findingstranslate","studies","combining","into","phasei","first-in-human","such","advancedsolid","malignancies","res","78(18)","5398-407","Â©2018","aacr"
